Graphite Bio is discontinuing the development of nulabeglogene autogedtemcel (nula-cel), its lead asset, and shaving off about 50% of its workforce.
Posts
Moderna Inc. will collaborate with privately owned Life Edit Therapeutics Inc. under an agreement to discover and develop mRNA gene-editing therapies, the companies said on Wednesday.
Tuesday, de-extinction company Colossal Biosciences closed a mammoth, $150 million Series B financing round and announced plans to resurrect the iconic Dodo – extinct since the 17th century.
The two companies first collaborated on gene-editing medicines in 2018, when Vertex made a $30 million upfront payment in a cystic fibrosis deal. In 2021, Vertex pledged up to $1.2 billion in milestone payments to expand this partnership to include ex vivo next-generation cell therapies for diabetes and blood diseases.
Pfizer Inc. is exploring options for some early-stage treatments for rare diseases and cancer in a bid to focus on “high-impact” medicines and vaccines, the company said on Thursday.
French biotech Cellectis said on Thursday it will take a 19% stake in the gene-editing technology startup Primera Therapeutics, launched by the private firm Mayflower Bioventures.
Pittsburgh-based NeuBase is diverting resources from its Huntington’s program and shedding 60% of its workforce in a strategic restructuring, the company announced Friday.
Precision BioSciences entered into an exclusive global in vivo gene editing research and development collaboration and license deal with Novartis Pharma. The two companies will work to develop a potential cure for hemoglobinopathies such as sickle cell disease and beta-thalassemia.
